BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Background Blood urea/creatinine (U/Cr) ratio is considered to be an ideal biomarker of dehydration. We investigated the association between the U/Cr ratio trajectory and delayed cerebral ischemia ...

China's biotechnology sector is experiencing notable growth, with the ChinaAMC Hang Seng Biotech ETF, tracking the Hang Seng ...

Aston Martin says the DBX 707 is an SUV like no other and we don’t think they’re far off the mark.

Urogen Pharma Ltd. plans to launch its new product July 1 after the firm overcame a decidedly mixed FDA advisory panel meeting to nail down approval June 12 of Zusduri (mitomycin, formerly known as ...

Thousands of Sam Fender fans descend on Newcastle for the first of three gigs at St James' Park.

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

The company PFE announced late Monday a license agreement with China-based 3SBio Inc. HK:1530 to develop, make and sell an antibody — SSGJ-707 — that targets PD-1 and VEGF, which suppresses ...

About two weeks ago, Pfizer has, for example, signed an exclusive global licensing deal with China’s 3SBio for the development of the company’s cancer drug candidate SSGJ-707, which is ...

This followed its overseas licensing deal - the company granted Pfizer global rights (excluding mainland China) for its self-developed PD-1/VEGF bispecific antibody SSGJ-707. The agreement includes a ...

BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. Per the terms, BMY will make an upfront ...